Statin Use in Hospitalized Patients with COVID-19: A Comprehensive Analysis of the New York City Public Hospital System - 16/06/22
Abstract |
Introduction |
Statins have been commonly used for primary and secondary cardiovascular prevention. We hypothesized that statins may improve in-hospital outcomes for hospitalized patients with Coronavirus disease 2019 (COVID-19) due to its known anti-inflammatory effects.
Methods |
We conducted a retrospective study at the largest municipal health care system in the United States, including adult patients who were hospitalized for COVID-19 between March 1 and December 1, 2020. The primary endpoint was in-hospital death. Propensity score matching was conducted to balance possible confounding variables between patients receiving statins during hospitalization (statin group) and those not receiving statins (non-statin group). Multivariate logistic regression was used to evaluate the association of statin use and other variables with in-hospital outcomes.
Results |
There were 8897 patients eligible for study enrollment, with 3359 patients in the statin group and 5538 patients in the non-statin group. After propensity score matching, both the statin and non-statin groups included 2817 patients. Multivariate logistic regression analysis showed that the statin group had a significantly lower risk of in-hospital mortality (odds ratio 0.71; 95% confidence interval, 0.63-0.80; P < .001) and mechanical ventilation (OR 0.80; 95% confidence interval, 0.71-0.90; P < .001) compared with the non-statin group.
Conclusion |
Statin use was associated with lower likelihood of in-hospital mortality and invasive mechanical ventilation in hospitalized patients with COVID-19.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, In-hospital mortality, Mechanical ventilation, Statin
Plan
Funding: None. |
|
Conflicts of Interest: None. |
|
Authorship: All authors had access to the data and contributed to writing the manuscript. |
|
This work was approved by the Biomedical Research Alliance of New York (BRANY) Institutional Review Board (IRB number 20-12-228-373). |
Vol 135 - N° 7
P. 897-905 - juillet 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.